



The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences
 Parkinson's Disease Therapeutics Conference
 New York, NY
 October 24, 2012

Conference Program	
8.30	Breakfast
9.00 – 9.15	Welcome by Todd Sherer, PhD and Kalpana Merchant, PhD
9.15 – 10.55	<p>Symptomatic Therapies</p> <p><i>Charlotte Keywood, MBBS MRCP FFPM, Addex Pharma S.A.</i> “ADX48621-201: Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease”</p> <p><i>Martin Freed, MD, Civitas Therapeutics, Inc.</i> “Inhaled Levodopa as a Treatment for Intermittent Motor Fluctuations in Parkinson's Disease Patients”</p> <p><i>Stephen Hitchcock, PhD, Envoy Therapeutics</i> “Target Discovery and Validation Aimed at Highly Specific Modulation of the Indirect Pathway”</p> <p><i>Emer Leahy, PhD, PsychoGenics Inc.</i> <i>Per Svenningsson, MD, PhD, Karolinska Institutet and Karolinska University Hospital</i> “Proof-of-Concept Clinical Trial on the Use of the 5-HT1A/1B Partial Agonist Eltoprazine for Treatment of L-DOPA-Induced Dyskinesias”</p>
10.55 – 11.25	Networking Break/Poster Viewing
11:25 – 1.30	<p>Disease Modifying Therapies</p> <p><i>Ethan Burstein, PhD, Acadia Pharmaceuticals</i> “Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease”</p> <p><i>Robert E. Burke, MD, Columbia University</i> “Axon regeneration by mTor signaling: Neurorestoration for Parkinson's disease (PD)”</p> <p><i>Alastair D. Reith, PhD, GlaxoSmithKline Pharmaceuticals R&D</i> “Translation of LRRK2 Clinical Genetics to Drug Discovery and Remaining Challenges”</p> <p><i>Jeffry B. Stock, PhD, Princeton University and Signum Biosciences, Inc.</i> “Targeting Alpha-Synuclein Dephosphorylation via PP2A Activation as a Novel PD Therapeutic”</p> <p><i>Howard E. Gendelman, MD, University of Nebraska Medical Center</i> “Biomarkers and Immunotherapy for Parkinson's Disease”</p>

1.30 – 2.30	Lunch/Poster Viewing
2.30 – 3.45	<p>Research Tools and Resources</p> <p><i>David John Burn FRCP, MD, MA, MB BS, Institute for Ageing and Health, Newcastle University</i> “Clinical Trial to Compare Cognitive Scales”</p> <p><i>Chester A. Mathis, PhD, University of Pittsburgh</i> “Consortium to Develop an Alpha-Synuclein Imaging Agent”</p> <p><i>Jing Zhang MD, PhD, University of Washington</i> “Using Human Cerebrospinal Fluid Samples Collected in DATATOP Study for Biomarker Validation in Patients with Parkinson disease”</p>
3.45 – 4.15	Networking Break/Poster Viewing
4.15 – 5.15	<p>Hot Topics in Parkinson’s Disease Research</p> <p><i>John Dunlop, PhD, AstraZeneca</i> “Parkinson's Disease and the Autophagy Pathway: Kill or Key?”</p> <p><i>Bernard Ravina, MD, MSCE, BiogenIdec</i> “Pre-Motor Parkinson's Disease: Implications for Clinical Trials”</p>
5.15 – 5.30	Closing Remarks
5.30 – 7.00	Cocktail Reception/Poster Viewing